(The FDA has received more than 700 adverse event reports tied to compounded GLP-1s, but its not clear if the events were caused by the drugs.) The companies also see compounders as a threat to their obesity drug sales, which are estimated to balloon to $100 billion a year by 2030
Clinical trials show weight loss outcomes of up to 15%, with additional benefits including reduced A1C levels and cardiovascular improvements Key Benefits of GLP-1 Therapies: Enhanced insulin sensitivity Lower blood sugar levels Reduced visceral fat and improved lipid profiles Improved cardiovascular health Decreased inflammation linked to chronic disease Source: Glucagon-like peptide 1 in health and disease
Lilly also has broader ambitions for orforglipron beyond obesity
Tip: rotate injection sites (abdomen one week, thigh the next, etc.) to avoid soreness in one spot
Insulin: Ultra-Rapid Acting This type is designed to dissolve rapidly at the injection site and begin lowering blood glucose almost immediately before a meal
GLP-1 SM 10MG is supplied for laboratory and research use only in research related to the action of GLP-1 receptor agonists and related metabolic pathway activities